CPT 81442: Genomic Sequence Analysis Panel for Noonan-Spectrum Disorders

CPT code 81442 represents a genomic sequence analysis panel targeting at least 12 genes linked to Noonan-spectrum disorders, which include pediatric developmental conditions with heart defects and distinctive physical features. This code is nationally significant as it supports advanced genetic testing for patients with suspected Noonan-spectrum disorders, facilitating accurate diagnosis and guiding clinical management. The procedure is classified under Pathology and Laboratory Procedures and is most commonly performed in independent laboratory settings.

Major national payers such as Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare provide coverage for this service, reflecting its clinical importance and widespread adoption. Readers will gain insight into payer coverage benchmarks, relevant policy updates, and the clinical context for the use of CPT code 81442. The publication also highlights associated modifiers, taxonomies, and ICD-10 diagnoses relevant to billing and coding, as well as related CPT codes for other genomic panels. This summary provides a comprehensive overview for stakeholders seeking to understand the billing, coverage, and clinical landscape for genomic testing in Noonan-spectrum disorders.

CPT Code Overview

CPT code 81442 is used for genomic sequence analysis panels that evaluate at least 12 genes associated with Noonan-spectrum disorders. These disorders are characterized by pediatric developmental issues, heart defects, distinctive craniofacial features, and skin and hair abnormalities. The service falls under Pathology and Laboratory Procedures, with testing typically performed at an Independent Laboratory (Place of Service 81). This code enables comprehensive genetic assessment to support clinical diagnosis and management of Noonan-spectrum conditions.

Clinical Context

A pediatric patient presents with developmental delays, congenital heart defects, and distinctive craniofacial features. The clinical team suspects a Noonan-spectrum disorder based on physical examination and family history. The physician orders a genomic sequence analysis panel (CPT 81442) to evaluate at least 12 genes associated with Noonan-spectrum disorders. The specimen is collected and sent to an independent laboratory (Place of Service 81), where a molecular genetic pathologist interprets the results. The findings assist in confirming the diagnosis and guiding further management.

Coding Specifications

Modifier 26: Used to indicate the professional component of the service, such as interpretation of the genomic analysis by a pathologist.
Modifier 59: Used to identify a distinct procedural service, indicating that the genomic panel is separate from other procedures performed on the same day.

Provider Taxonomy Code	Specialty Description
`207ZP0102X`

For CPT code 81442, national mean rates among commercial payers (BUCA) are $1,474.26, which are substantially higher than typical Medicare rates, though Medicare data is not available in the input for this code. Blue Cross Blue Shield and Cigna report the highest mean rates nationally, at $1,695.15 and $1,606.53 respectively, while Aetna is the lowest among the major commercial payers at $1,280.90.

Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna exhibits the widest spread ($2,283.00 - $581.19 = $1,701.81), indicating greater variability in contracted rates. In contrast, Aetna shows the tightest range ($1,757.00 - $517.00 = $1,240.00), suggesting more consistent pricing. UnitedHealth Group and BUCA also display moderate dispersion, while Blue Cross Blue Shield's range is $973.57.

The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.

Related Diagnoses

C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung. May be relevant if a Noonan-spectrum disorder patient presents with a lung neoplasm, as some genetic syndromes increase cancer risk.
C50.919: Malignant neoplasm of unspecified site of unspecified female breast. Used if a patient with Noonan-spectrum disorder is found to have a breast neoplasm, supporting comprehensive genetic evaluation.
C18.9: Malignant neoplasm of colon, unspecified. Relevant for patients with Noonan-spectrum disorder and colon neoplasm, as genetic syndromes may predispose to malignancies.
C61: Malignant neoplasm of prostate. Used when a male patient with Noonan-spectrum disorder presents with prostate cancer, indicating the need for genetic analysis.
C25.9: Malignant neoplasm of pancreas, unspecified. Applied if a Noonan-spectrum disorder patient is diagnosed with pancreatic cancer, supporting the use of genomic analysis to assess genetic risk.

These diagnoses are clinically relevant as Noonan-spectrum disorders may be associated with increased risk for certain malignancies, warranting genomic evaluation.

Related CPT Codes

81440: Genomic sequence analysis panel to evaluate at least 100 mitochondrial genes related to nerve or muscle pathologies. Used for patients with suspected mitochondrial disorders; not typically performed together with 81442 but may be considered in differential diagnosis.
81441: Genomic sequence analysis panel of at least 30 genes for inherited bone marrow failure syndromes (IBMFS). Relevant for patients with suspected IBMFS; serves as an alternative to 81442 when clinical suspicion is for bone marrow failure.
81443: Genomic sequence analysis panel of at least 15 genes related to severe inherited conditions, many in Ashkenazi Jewish descent. Used for targeted population screening; not commonly performed with 81442 but may be considered in cases with overlapping clinical features.
81445: Genomic sequence analysis panel of 5‑50 genes in solid organ neoplasms, DNA and possibly RNA alterations. Used in oncology for tumor profiling; not typically performed with 81442 but may be ordered in cases where a neoplasm is suspected alongside a genetic syndrome.

These codes are related by their use of genomic sequencing panels but target different clinical conditions. They are alternatives or adjuncts depending on the patient's presentation.

The table and chart below present a detailed breakdown of national benchmarks for each payer, including mean rates and percentile values.

OpenPayer

Summary & Overview